Detlev Biniszkiewicz Net Worth

The estimated Net Worth of Detlev Biniszkiewicz is at least 56 千$ dollars as of 3 January 2022. Detlev Biniszkiewicz owns over 3,500 units of iTeos Therapeutics stock worth over 55,965$ and over the last 4 years Detlev sold ITOS stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Detlev Biniszkiewicz ITOS stock SEC Form 4 insiders trading

Detlev has made over 1 trades of the iTeos Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently Detlev exercised 3,500 units of ITOS stock worth 66,500$ on 3 January 2022.

The largest trade Detlev's ever made was exercising 3,500 units of iTeos Therapeutics stock on 3 January 2022 worth over 66,500$. On average, Detlev trades about 875 units every 0 days since 2020. As of 3 January 2022 Detlev still owns at least 3,500 units of iTeos Therapeutics stock.

You can see the complete history of Detlev Biniszkiewicz stock trades at the bottom of the page.

What's Detlev Biniszkiewicz's mailing address?

Detlev's mailing address filed with the SEC is C/O ITEOS THERAPEUTICS, INC., 321 ARSENAL STREET, WATERTOWN, MA, 02472.

Insiders trading at iTeos Therapeutics

Over the last 4 years, insiders at iTeos Therapeutics have traded over 196,492,023$ worth of iTeos Therapeutics stock and bought 4,975,000 units worth 95,182,800$ . The most active insiders traders include Capital Management, L.P.Ra ...、Capital Management, L.P.Kol...、Aaron I. Davis. On average, iTeos Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of 1,817,279$. The most recent stock trade was executed by Matthew Gall on 12 October 2023, trading 5,000 units of ITOS stock currently worth 41,850$.

What does iTeos Therapeutics do?

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Complete history of Detlev Biniszkiewicz stock trades at iTeos Therapeutics

iTeos Therapeutics executives and stock owners

iTeos Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Michel Detheux Ph.D.,
  Pres, CEO & Director
• Dr. Michel Detheux,
  Pres, CEO & Director
• Dr. Joanne Jenkins Lager M.D.,
  Chief Medical Officer
• Matthew Gall,
  Chief Financial Officer
• Philippe Brantegem,
  Vice-Pres of HR
• Ryan Baker,
  Head of Investor Relations
• Matthew A. Call M.B.A.,
  Chief Operating Officer
• David Feltquate,
  Chief Medical Officer
• Bio Ventures 2014, L.P.Evni...,
  
• Capital Management, L.P.Kol...,
  
• Capital, Llc Boxer Asset Ma...,
  
• Aaron I. Davis,
  
• Ann D Rhoads,
  
• Ansbert Gadicke,
  Director
• Derek Di Rocco,
  Director
• David Hallal,
  
• Detlev Biniszkiewicz,
  Director
• Capital, Llc Boxer Asset Ma...,
  
• Hauwermeiren Timothy Van,
  
• Ansbertubs Oncology Impact ...,
  
• Bio Ventures 2014, L.P.Mpm ...,
  
• Matthew Roden,
  Director
• Matthew Call,
  Chief Operating Officer
• Yvonne Mc Grath,
  Chief Scientific Officer
• Joanne Jenkins Lager,
  Chief Medical Officer
• Robert Iannone,
  
• Capital Management, L.P.Ra ...,
  
• Bio Ventures 2014, L.P.Evni...,
  
• Bioventures 2018, L.P.Mpm B...,
  
• Ansbertubs Oncology Impact ...,
  
• Ansbertubs Oncology Impact ...,
  
• Capital, Llc Boxer Asset Ma...,
  
• Capital, Llc Boxer Asset Ma...,
  
• David K Lee,
  
• Michel Detheux,
  Chief Executive Officer
• Matthew Gall,
  Chief Financial Officer
• Jill De Simone,
  
• Tony W Ho,